2,750 results on '"Dummer, R"'
Search Results
152. Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
153. Basal cell carcinomas in a tertiary referral centre: a systematic analysis
154. PLATForM : Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
155. Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600) mutated melanoma : first data from a multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERINGMELANOMA
156. MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)
157. A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences*
158. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
159. 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) plus binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
160. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
161. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
162. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
163. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
164. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling
165. Real-life data for first-line combination immune- checkpoint inhibition and targeted therapy in patients with melanoma brain metastases
166. Staging and prognostic factors
167. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
168. A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences*
169. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial
170. Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma
171. LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial
172. 1180TiP Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma
173. 1177P Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
174. 1127P Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis
175. 1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
176. 1104P Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
177. 1083MO Brain metastases and survival evaluation in the SECOMBIT trial
178. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
179. In melanoma, beta-catenin is a suppressor of invasion
180. Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model
181. Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
182. Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
183. Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
184. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
185. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
186. Topische Phospholipide bei kutanen Lymphomen
187. Topische Behandlung kutaner T-Zell-Lymphome mit Carmustin (BCNU)
188. Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma
189. Methylation dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma: CS51
190. BOLT - eine randomisierte, doppelblinde Studie mit Sonidegib (LDE225) bei Patienten mit lokal fortgeschrittenem oder metastasiertem Basalzellkarzinom: FV4
191. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma
192. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas
193. Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)
194. A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences*
195. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
196. Evolving impact of long-term survival results on metastatic melanoma treatment
197. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
198. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
199. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
200. Response to: Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.